Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
30 mars 2020 06h05 HE
|
Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 08h35 HE
|
Cocrystal Pharma, Inc.
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – –...
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
12 nov. 2018 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
11 mai 2018 08h00 HE
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Achillion Appoints Dr. Frank Verwiel to Board of Directors
16 déc. 2015 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
05 nov. 2015 17h51 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...